199 related articles for article (PubMed ID: 20948320)
1. Clinical and biological impact of EphA2 overexpression and angiogenesis in endometrial cancer.
Merritt WM; Kamat AA; Hwang JY; Bottsford-Miller J; Lu C; Lin YG; Coffey D; Spannuth WA; Nugent E; Han LY; Landen CN; Nick AM; Stone RL; Coffman K; Bruckheimer E; Broaddus RR; Gershenson DM; Coleman RL; Sood AK
Cancer Biol Ther; 2010 Dec; 10(12):1306-14. PubMed ID: 20948320
[TBL] [Abstract][Full Text] [Related]
2. Clinical and biological significance of vascular endothelial growth factor in endometrial cancer.
Kamat AA; Merritt WM; Coffey D; Lin YG; Patel PR; Broaddus R; Nugent E; Han LY; Landen CN; Spannuth WA; Lu C; Coleman RL; Gershenson DM; Sood AK
Clin Cancer Res; 2007 Dec; 13(24):7487-95. PubMed ID: 18094433
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer.
Landen CN; Lu C; Han LY; Coffman KT; Bruckheimer E; Halder J; Mangala LS; Merritt WM; Lin YG; Gao C; Schmandt R; Kamat AA; Li Y; Thaker P; Gershenson DM; Parikh NU; Gallick GE; Kinch MS; Sood AK
J Natl Cancer Inst; 2006 Nov; 98(21):1558-70. PubMed ID: 17077358
[TBL] [Abstract][Full Text] [Related]
4. EphA2 overexpression is associated with lack of hormone receptor expression and poor outcome in endometrial cancer.
Kamat AA; Coffey D; Merritt WM; Nugent E; Urbauer D; Lin YG; Edwards C; Broaddus R; Coleman RL; Sood AK
Cancer; 2009 Jun; 115(12):2684-92. PubMed ID: 19396818
[TBL] [Abstract][Full Text] [Related]
5. EphA2 targeted chemotherapy using an antibody drug conjugate in endometrial carcinoma.
Lee JW; Stone RL; Lee SJ; Nam EJ; Roh JW; Nick AM; Han HD; Shahzad MM; Kim HS; Mangala LS; Jennings NB; Mao S; Gooya J; Jackson D; Coleman RL; Sood AK
Clin Cancer Res; 2010 May; 16(9):2562-70. PubMed ID: 20388851
[TBL] [Abstract][Full Text] [Related]
6. Dual targeting of EphA2 and ER restores tamoxifen sensitivity in ER/EphA2-positive breast cancer.
Gökmen-Polar Y; Toroni RA; Hocevar BA; Badve S; Zhao Q; Shen C; Bruckheimer E; Kinch MS; Miller KD
Breast Cancer Res Treat; 2011 Jun; 127(2):375-84. PubMed ID: 20602165
[TBL] [Abstract][Full Text] [Related]
7. Expression of EphA2 and VEGF in squamous cell carcinoma of the tongue: correlation with the angiogenesis and clinical outcome.
Shao Z; Zhang WF; Chen XM; Shang ZJ
Oral Oncol; 2008 Dec; 44(12):1110-7. PubMed ID: 18485799
[TBL] [Abstract][Full Text] [Related]
8. Combination of EphA2- and Wee1-Targeted Therapies in Endometrial Cancer.
Dasari SK; Joseph R; Umamaheswaran S; Mangala LS; Bayraktar E; Rodriguez-Aguayo C; Wu Y; Nguyen N; Powell RT; Sobieski M; Liu Y; Chowdhury MA; Amero P; Stephan C; Lopez-Berestein G; Westin SN; Sood AK
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835335
[TBL] [Abstract][Full Text] [Related]
9. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in endometrial carcinoma.
Guidi AJ; Abu-Jawdeh G; Tognazzi K; Dvorak HF; Brown LF
Cancer; 1996 Aug; 78(3):454-60. PubMed ID: 8697391
[TBL] [Abstract][Full Text] [Related]
10. Fatty acid synthase is a potential therapeutic target in estrogen receptor-/progesterone receptor-positive endometrioid endometrial cancer.
Rahman MT; Nakayama K; Ishikawa M; Rahman M; Katagiri H; Katagiri A; Ishibashi T; Iida K; Miyazaki K
Oncology; 2013; 84(3):166-73. PubMed ID: 23306391
[TBL] [Abstract][Full Text] [Related]
11. EphA2- and HDAC-Targeted Combination Therapy in Endometrial Cancer.
Joseph R; Dasari SK; Umamaheswaran S; Mangala LS; Bayraktar E; Rodriguez-Aguayo C; Wu Y; Nguyen N; Powell RT; Sobieski M; Liu Y; Kim MS; Corvigno S; Foster K; Hanjra P; Vu TC; Chowdhury MA; Amero P; Stephan C; Lopez-Berestein G; Westin SN; Sood AK
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38279277
[TBL] [Abstract][Full Text] [Related]
12. DNMT3A/3B overexpression might be correlated with poor patient survival, hypermethylation and low expression of ESR1/PGR in endometrioid carcinoma: an analysis of The Cancer Genome Atlas.
He D; Wang X; Zhang Y; Zhao J; Han R; Dong Y
Chin Med J (Engl); 2019 Jan; 132(2):161-170. PubMed ID: 30614867
[TBL] [Abstract][Full Text] [Related]
13. Impact of hormonal biomarkers on response to hormonal therapy in advanced and recurrent endometrial cancer.
van Weelden WJ; Lalisang RI; Bulten J; Lindemann K; van Beekhuizen HJ; Trum H; Boll D; Werner HMJ; van Lonkhuijzen LRCW; Yigit R; Forsse D; Witteveen PO; Galaal K; van Ginkel A; Bignotti E; Weinberger V; Sweegers S; Kroep JR; Cabrera S; Snijders MPLM; Inda MA; Eriksson AGZ; ; Krakstad C; Romano A; van de Stolpe A; Pijnenborg JMA
Am J Obstet Gynecol; 2021 Oct; 225(4):407.e1-407.e16. PubMed ID: 34019887
[TBL] [Abstract][Full Text] [Related]
14. Hypoxia contributes to development of recurrent endometrial carcinoma.
Pijnenborg JM; Wijnakker M; Hagelstein J; Delvoux B; Groothuis PG
Int J Gynecol Cancer; 2007; 17(4):897-904. PubMed ID: 17359291
[TBL] [Abstract][Full Text] [Related]
15. The analysis of hormonal status and vascular and cell proliferation in endometrioid endometrial adenocarcinomas.
Drocaş I; Crăiţoiu Ş; Stepan AE; Iliescu DG; Drocaş IA; Stepan MD
Rom J Morphol Embryol; 2022; 63(1):113-120. PubMed ID: 36074674
[TBL] [Abstract][Full Text] [Related]
16. Coordinate expression of Cdc25B and ER-alpha is frequent in low-grade endometrioid endometrial carcinoma but uncommon in high-grade endometrioid and nonendometrioid carcinomas.
Wu W; Slomovitz BM; Celestino J; Chung L; Thornton A; Lu KH
Cancer Res; 2003 Oct; 63(19):6195-9. PubMed ID: 14559803
[TBL] [Abstract][Full Text] [Related]
17. EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma.
Lee JW; Han HD; Shahzad MM; Kim SW; Mangala LS; Nick AM; Lu C; Langley RR; Schmandt R; Kim HS; Mao S; Gooya J; Fazenbaker C; Jackson D; Tice DA; Landen CN; Coleman RL; Sood AK
J Natl Cancer Inst; 2009 Sep; 101(17):1193-205. PubMed ID: 19641174
[TBL] [Abstract][Full Text] [Related]
18. Vascular endothelial growth factor-D over-expressing tumor cells induce differential effects on uterine vasculature in a mouse model of endometrial cancer.
Girling JE; Donoghue JF; Lederman FL; Cann LM; Achen MG; Stacker SA; Rogers PA
Reprod Biol Endocrinol; 2010 Jul; 8():84. PubMed ID: 20615255
[TBL] [Abstract][Full Text] [Related]
19. Antiangiogenic and antitumor efficacy of EphA2 receptor antagonist.
Dobrzanski P; Hunter K; Jones-Bolin S; Chang H; Robinson C; Pritchard S; Zhao H; Ruggeri B
Cancer Res; 2004 Feb; 64(3):910-9. PubMed ID: 14871820
[TBL] [Abstract][Full Text] [Related]
20. Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression.
Lax SF; Pizer ES; Ronnett BM; Kurman RJ
Hum Pathol; 1998 Jun; 29(6):551-8. PubMed ID: 9635673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
